J&J unit gets expanded approval in Europe for drug-coated stent

02/17/2009 | Pharmaceutical Business Review Online

The European Union has granted CE Mark approval to Cordis, a Johnson & Johnson unit, to market a drug-coated stent for the treatment of patients with diabetes. The Cypher Select Plus Sirolimus-eluting coronary stent features the CYPH2ONIC hydrophilic coating technology that offers more flexibility to doctors in moving into hard-to-navigate coronary arteries.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC